Failure of basic protein therapy for multiple sclerosis.
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
L Demonty
Publications and source records attributed to L Demonty.
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
140 MS patients were treated with intensive I.V. cyclophosphamide immunotherapy and 110 were followed over 2-4 years. Annual relapse rate incidence was calculated over a period of 2 years before and after treatment and repeated neurological scores were made during this period. The conclusions are that 62% of the patients were stabilized during 2-4 years and that clinical improvement of the neurological signs was observed in most of the cases. It is concluded that intensive immunosuppression is able to interfere with the pathological processes involved in the pathogenesis of disseminated sclerosis.
Adult↗
Biochemical findings in multiple sclerosis. II. A detailed study of the serum IgA, IgG and IgM levels of 772 MS patients compared with 226 neurological controls.
In the second paper of this series, a detailed study of the three main serum immunoglobulins for a group of 772 MS patients is compared with a group of 226 neurological controls. The results are studied according to sex and different age groups. Except for a slight elevation of the IGM levels in the MS group, especially between 40 and 60 years, no clear cut distinction between the two groups of patients was found.
Adult↗
[Clinical study of sodium dantroline (Dantrium) in multiple sclerosis (author's transl)].
The authors have studied the antispastic action of Dantrium in 50 patients with multiple sclerosis; in all cases, hypertonia, spasms or clonus constituted a severe obstacle to remedial therapy or nursing. After one year, the authors have found that Dantrium is effective in reducing hypertonia in 40% of the patients, in improving spasms in 65% and in reducing clonus in 50% of the cases. Secondary effects are fairly frequent (60%), characterized in most cases by diminished muscular strength and greater fatigability.
Clinical Trials as Topic↗